The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, ...

Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...

Both incident and recurrent heart failure hospitalization risk is associated with post-traumatic stress disorder among patients with CAD.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Many studies have reported that obesity causes heart failure (HF) pathogenesis.

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.